Search

The article describes the viral corneal infections or herpes simplex virus (HSV) which remains the leading cause of herpetic ocular incidents. Diagnostic options for HSV include herpes culture-fluorescent antibody, DNA amplification, Tzanck smear, and serum antibody testing. Topical treatment strategies for HSV include antibiotics, steroids, and antivirals like trifluridine, vidarabine and ganciclovir.

The article offers information on the symptoms, pathophysiology, and treatment and management of herpes simplex virus (HSV) epithelial keratitis which is the second most common ocular manifestation of HSV. Topics include recurrence of the HSV infection, transmission of virus which occurs via bodily fluids and affects the skin and mucous membranes of the infected host and use of ganciclovir as an alternative to trifluridine.

The article discusses the symptoms associated with viral eye infections along with the preventive measures and therapeutic approaches which should be undertaken for its treatment. It mentions that the herpes family of viruses is the primarily infectious agents which causes red inflamed eye and can also elicit immune and inflammatory response. It recommends taking ganciclovir, trifluridine and acyclovir antiviral agents for its remedy. INSETS: Primary HSV Infection;Herpes Zoster Disease;Give Zostavax a Shot;'Tips' to Make the Correct Diagnosis

The article focuses on the diagnosis and treatment of herpes simplex virus (HSV) keratitis. It presents statistics on the disease's prevalence and cites considerations for differential diagnosis of HSV. It discusses the antiviral therapy for HSV which includes the use of topical corticosteroids plus antiviral cover for immunological HSV forms and topical ophthalmic antivirals. It also cites a clinical trial evaluating the efficacy of 0.15% ganciclovir gel for adenovirus keratoconjunctivitis.

The article offers information on the diagnosis and management of various types of conjunctivitis. It mentions that pharyngoconjunctival fever (PCF) occurs on patients with viral conjunctivitis. It states that the standard of care for viral conjunctivitis is topical ganciclovir. It states that ulceration of the eyelid, watery discharge, and vesicular rash are signs of herpetic conjunctivitis. It argues that clinicians need to accurately differentiate the types of conjunctivitis for treatment.

The article explores treatment options for infectious retinitis. Cytomegalovirus (CMV) retinitis can occur in AIDS patients, neonates and those in whom immunosuppression was induced. According to ophthalmology professor J. Fernando Arevalo, CMV retinitis can be treated with intravenous ganciclovir or oral valganciclovir, intravitreal antiviral drug implants or surgery. Choosing the best surgical option depends on the mechanical factors of the retinal detachment as well as patient factors.

The article reports on the approval of the U.S. Food and Drug Administration (FDA) of ganciclovir ophthalmic gel 0.15% which is used to treat acute herpetic keratitis. The approval brings ophthalmologists a significant advancement in topical antiviral therapy for a condition which is the leading cause of corneal blindness in the country. Susan Benton, senior vice president of sales and marketing for Sirion Therapeutics Inc., the approved gel is their second product approval in 15 months.

The article addresses certain issues related to use of intravitreal injections for treatment of various retinal diseases. For the treatment of CMV retinitis, intravitreal ganciclovir and foscarnet injections were utilized in the early 1990s. Over the past five years triamcinolone acetonide injections have been used increasingly for a variety of retinal diseases. Although results of definitive randomized clinical trials are still pending, preliminary evidence from case series supported by frequent clinical use has given hope for these treatments in reversing visual loss from many otherwise blinding retinal diseases.

The article discusses the importance for clinicians to discern which antiviral drugs may be best approach in managing patients with viral eye disease, adapted from Dr. Todd P. Margolis' presentation at Cornea Subspecialty Day during the 2017 meeting of the American Academy of Ophthalmology. Topics covered include the need to consider the cost and side effects of the medication, the dosing for three systemic antivirals that are equally effective, and the steroid regimen to treat inflammation.

Discusses a study which explored the effect of administering oral ganciclovir combined with a ganciclovir intraocular implant on the incidence of cytomegalovirus (CMV) disease and retinitis in patients with AIDS and CMV retinitis. Comments from Daniel F. Martin, lead author of the study; How the study was conducted; Dosage and administration of the ganciclovir; Median time to progression of retinitis among patients assigned to intravenous ganciclovir.

The article describes the case of a 52-year-old woman who had poor vision with her right eye that lasted for 1 month. She was diagnosed to having a frosted branch angiitis caused by cytomegalovirus retinitis, as those diseases were associated to her health being diminished by human immuno virus. The woman was initially treated with an immediate intravitreal ganciclovir vaccine and was admitted to a local hospital for further diagnosis and treatment.

The article highlights the presentation of Tammy P. Than at the 2011 Southeastern Conference of Optometry (SECO) meeting about the developments in ophthalmic therapy. He offered update on anti-infectives, treatment for ocular surface disease, anti-allergy drugs, topical steroids, and related topic. Products he cited include a ganciclovir ophthalmic gel from Bausch + Lomb, an alcaftadine ophthalmic solution from Vistakon Pharmaceuticals, and a metallo-organic compound from OPKO Health.

The article discusses the concepts of the antiherpetic drug ganciclovir. It mentions that the drug would demonstrate a dual mechanism that would effectively target cells infected by herpes simplex virus (HSV). It states that the viral thymidine kinase, which is found in HSV-infected cells, would phosphorylate the ganciclovir. Furthermore, the drug had proven that the toxic in HSV-infected cells are high to achieve significant drug activation.

The article offers information on the effectiveness of ganciclovir ophthalmic gel 0.15% (Zirgan) for the treatment of herpetic keratitis, a leading infectious cause of corneal blindness and a potential indication for corneal transplantation in U.S. and Europe. It offers significant risk information for ganciclover ophthalmic gel and the approval of the U.S. Food and Drug Administration (USDA) of such gel. It also cites the use of acyclovir as an option for dendritic herpes keratitis' treatment.

The article reports that Bausch & Lomb Inc. has acquired the assets and U.S. rights for ganciclovir ophthalmic gel 0.5% from Sirion Therapeutics Inc. in Rochester, New York. It notes that the Food and Drug Administration (FDA) has approved ganciclovir ophthalmic gel as a topical antiviral for the management of acute herpetic keratitis. Statements from Bausch & Lomb chief executive officer (CEO) Brent Saunders concerning the company's acquisition are also presented.

The article discusses the clinical care of a 21-year-old female who was diagnosed with Herpes simplex virus (HSV) keratitis. The patient complained of sharp pain in her right eye every 10 to 15 minutes. Slit lamp examination on the patient's eyes showed bulbar conjunctival injection in the right eye, coalesced superficial punctate keratitis (SPK) and underlying keratic precipitates (KP). Dry eye, Posner-Schlossman syndrome and herpetic keratouveitis were considered for differential diagnosis. The patient was placed under a treatment regimen that included trifluridine, ganciclovir ophthalmic gel, loteprednolol ophthalmic suspension and steroids.

The article presents a discussion of the use of ganciclovir gel for the treatment of herpes viruses, adapted from a presentation by Dr. Kristin Hammersmith during Cornea Subspecialty Day at the 2015 meeting of the American Academy of Ophthalmology. Topics covered include the effectiveness of topical ganciclovir gel in treating herpes simplex epithelial keratitis, the comparison between ganciclovir and acyclovir, and the potential of ganciclovir to treat adenovirus.

The article focuses on the approval of Zirgan, a formulation of ganciclovir in a topical gel form, by the U.S. Food and Drug Administration (FDA). It notes that this FDA approved drug is for treating herpetic keratitis. Furthermore, the drug's approval is based on results of Virgan clinical trials conducted in the 1990s by Laboratories Théa in Europe, Asia and Africa.

The article reports on the development of drug delivery systems in the U.S. The development includes the Posudex implant, which is aimed at treating diabetic macular edema. The ganciclovir implant provided a high and steady concentration of the drug in the vitreous cavity. However, the Retisert implant was approved for the treatment of posterior uveitis. The national eye institute (NEI) has offered a $7 million grant to support transscleral drug delivery devices.

The article examines the effect of intravenous ganciclovir as treatment in patients with symptomatic congenital cytomegalovirus (CMV) infection, a common cause of mental retardation and hearing loss.

Focuses on research trials using ganciclovir to treat cytomegalovirus (CMV) retinitis. Role of CMV retinitis in causing infectious retinitis; treatment of CMV retinitis through systemic therapy and local therapy; Composition of systemic therapy including ganciclovir, foscarnet and cidofovir; Administration of local therapy via intraviteal injections and ganciclovir implants.

Reports on the result of a study conducted by National Institute of Allergy and Infectious Diseases (NIAID) and Hoffman-La Roche Inc. on the efficacy of oral ganciclovir for prophylaxis of cytomegalovirus (CMV) retinitis. Discrepancy on the result of the study; Difference in three areas of study; Examination of the same drug with identical patient population.

The article reports on the availability of Zirgan or ganciclovir ophthalmic gel as the topical antiviral agent for the treatment of acute herpetic dendritic keratitis. It is said that Zirgan effectively treats herpetic epithelial disease. It indicates that ganciclovir is a guanosine derivative and a potent inhibitor of the herpes virus family's members.

The article discusses the effectiveness of ganciclover ophthalmic gel 0.15% for the treatment of dendritic herpetic keratitis. It mentions the author's avoidance on the use of trifluridine ophthalmic solution due to its toxicity, her use of acyclovir to treat herpes simplex virus (HSV) keratitis before the introduction of ganciclovir ophthalmic gel, and its advantageous dosing and low rates of resistance. It further cites that such gel is a significant new option for U.S. ophthalmologists.

The article reports on a safe and effective treatment for herpes keratitis. Ganciclovir 0.15% gel is a safe treatment for herpes keratitis, the most common cause of corneal blindness as well as the third most common indication for corneal transplantation, reported researcher Khalid F. Tabbara during the American Academy of Ophthalmology annual meeting. Other anti-viral agents such as idoxuridine, vidarabine, trifluridine and acyclovir, have also been used for treating herpetic keratitis. However, prolonged use of these thymidine analogues poses a risk to the ocular surface.

Reports that oral ganciclovir combined with a ganciclovir implant seem to offer unilateral cytomegalovirus (CMV) retinitis patients a better prognosis. Comparison with the implant by itself or intravenous ganciclovir; Results of a trial; Reduction in the risk for Kaposi's sarcoma; Occurrence of resistance to ganciclovir.

Discusses the importance of ganciclovir implants in the treatment of cytomegalovirus retinitis. Sustained-release delivery device; Indications for implantation; Surgical procedure; Study which tracks lesions; Disadvantages; Availability of improved therapies against the human immunodeficiency virus (HIV).

Focuses on the surgical procedure of implanting Vitrasert intraocular sustained-release ganciclovir.

Reports on the findings of a study on the use of oral ganciclovir as prophylaxis in patients with cytomegalovirus (CM) diseases, presented at the Third Conference on Retroviruses and Opportunistic Infections. Information released by study overseer Roche Group; Risk of drug resistance in the use of ganciclovir; Background on CMV and ganciclovir.

Reports that Isis Pharmaceuticals will begin Phase II clinical trials on Isis 2922, an antisense compound used to treat AIDS patients infected with cytomegalovirus (CMV)-induced retinitis. Study design; Comparison of combined ISIS 2922/ganciclovir therapy to ganciclovir treatment alone; Results of Phase I/Phase II clinical trials.